BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025
BioCardia (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, announced its CEO Peter Altman's participation in a fireside chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2025. The presentation, scheduled for 3:40 p.m. EDT, will focus on recent business developments and the company's therapeutic pipeline, particularly highlighting their lead product CardiAMP, an autologous cell therapy for treating ischemic heart failure. The session will be moderated by Jim Molloy, AGP's Managing Director of Equity Research Biotechnology & Specialty Pharmaceuticals.
BioCardia (NASDAQ:BCDA), sviluppatore di terapie cellulari e derivate per malattie cardiovascolari e polmonari, ha annunciato la partecipazione del suo CEO Peter Altman a una conversazione informale durante il A.G.P. Virtual Healthcare Company Showcase il 21 maggio 2025. La presentazione, prevista per le 15:40 EDT, si concentrer脿 sugli ultimi sviluppi aziendali e sul portafoglio terapeutico dell'azienda, con particolare attenzione al loro prodotto principale CardiAMP, una terapia cellulare autologa per il trattamento dell'insufficienza cardiaca ischemica. La sessione sar脿 moderata da Jim Molloy, Direttore Generale della Ricerca Azionaria in Biotecnologie e Farmaceutica Specializzata di AGP.
BioCardia (NASDAQ:BCDA), desarrollador de terapias celulares y derivadas para enfermedades cardiovasculares y pulmonares, anunci贸 la participaci贸n de su CEO Peter Altman en una charla informal durante el A.G.P. Virtual Healthcare Company Showcase el 21 de mayo de 2025. La presentaci贸n, programada para las 3:40 p.m. EDT, se centrar谩 en los recientes avances comerciales y en la cartera terap茅utica de la compa帽铆a, destacando especialmente su producto principal CardiAMP, una terapia celular aut贸loga para el tratamiento de la insuficiencia card铆aca isqu茅mica. La sesi贸n ser谩 moderada por Jim Molloy, Director General de Investigaci贸n de Renta Variable en Biotecnolog铆a y Farmac茅utica Especializada de AGP.
BioCardia (NASDAQ:BCDA)電� 鞁槇甏� 氚� 韽� 歆堩櫂鞚� 鞙勴暅 靹疙彫 氚� 靹疙彫 鞙犽灅 旃橂鞝滊ゼ 臧滊皽頃橂姅 須岇偓搿�, CEO Peter Altman鞚� 2025雲� 5鞗� 21鞚� A.G.P. 臧�靸� 項姢旒�鞏� 須岇偓 靽检紑鞚挫姢鞐愳劀 歆勴枆霅橂姅 韺岇澊鞏挫偓鞚措摐 毂勴寘鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞚� 氚滍憸電� 霃欕秬 響滌鞁� 旮办 鞓ろ泟 3鞁� 40攵勳棎 鞓堨爼霅橃柎 鞛堨溂氅�, 斓滉芳 靷梾 臧滊皽瓿� 須岇偓鞚� 旃橂鞝� 韺岇澊頂勲澕鞚胳棎 欷戩爯鞚� 霊愱碃 韸鬼瀳 項堩槇靹� 鞁秬鞝勳潉 旃橂頃橁赴 鞙勴暅 鞛愱皜 靹疙彫 旃橂鞝滌澑 CardiAMP毳� 臧曥“頃� 鞓堨爼鞛呺媹雼�. 靹胳厴鞚� AGP鞚� 氚旍澊鞓ろ厡韥� 氚� 鞝勲 鞝滌暯 欤检嫕 鞐瓣惮 雼措嫻 靸侂鞚� Jim Molloy臧� 歆勴枆頃╇媹雼�.
BioCardia (NASDAQ:BCDA), d茅veloppeur de th茅rapies cellulaires et d茅riv茅es pour les maladies cardiovasculaires et pulmonaires, a annonc茅 la participation de son PDG Peter Altman 脿 une discussion informelle lors du A.G.P. Virtual Healthcare Company Showcase le 21 mai 2025. La pr茅sentation, pr茅vue 脿 15h40 EDT, portera sur les r茅cents d茅veloppements commerciaux et le pipeline th茅rapeutique de l'entreprise, mettant particuli猫rement en avant leur produit phare CardiAMP, une th茅rapie cellulaire autologue pour le traitement de l'insuffisance cardiaque isch茅mique. La session sera mod茅r茅e par Jim Molloy, directeur g茅n茅ral de la recherche actions en biotechnologie et produits pharmaceutiques sp茅cialis茅s chez AGP.
BioCardia (NASDAQ:BCDA), ein Entwickler von zellbasierten und zellabgeleiteten Therapeutika f眉r Herz-Kreislauf- und Lungenerkrankungen, gab die Teilnahme seines CEO Peter Altman an einem Fireside-Chat beim A.G.P. Virtual Healthcare Company Showcase am 21. Mai 2025 bekannt. Die Pr盲sentation, die f眉r 15:40 Uhr EDT geplant ist, wird sich auf aktuelle gesch盲ftliche Entwicklungen und die therapeutische Pipeline des Unternehmens konzentrieren, wobei besonders das f眉hrende Produkt CardiAMP, eine autologe Zelltherapie zur Behandlung von isch盲mischer Herzinsuffizienz, hervorgehoben wird. Die Sitzung wird von Jim Molloy, AGP's Managing Director f眉r Equity Research Biotechnologie & Spezialpharmazeutika, moderiert.
- None.
- None.
SUNNYVALE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that BioCardia鈥檚 CEO, Peter Altman, Ph.D., will participate in a fireside chat at the Alliance Global Partners Virtual Healthcare Company Showcase hosted by Jim Molloy, Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals at A.G.P., on May 21, 2025.
Dr. Altman will share recent business developments on the Company鈥檚 therapeutic development pipeline with a focus on its lead CardiAMP autologous cell therapy for the treatment of ischemic heart failure.
Fireside Chat Details:
Date: Wednesday, May 21, 2025
Time: 03:40 p.m. EDT
Speaker: Peter Altman Ph.D., CEO
Moderator: Jim Molloy, AGP Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals
Webcast:
About BioCardia庐
,聽headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP庐 autologous and CardiALLO鈩� allogeneic cell therapies are the Company鈥檚 biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix鈩� biotherapeutic delivery and Morph庐 vascular navigation product platforms. For more information visit .
MEDIA CONTACT: Miranda Peto, Investor Relations [email protected] (650) 226-0120 INVESTOR CONTACT: David McClung, Chief Financial Officer [email protected] (650) 226-0120
FAQ
What will BioCardia (BCDA) discuss at the A.G.P. Healthcare Showcase on May 21, 2025?
Who is presenting at BioCardia's (BCDA) fireside chat on May 21, 2025?
What is BioCardia's (BCDA) main product in development?
What time is BioCardia's (BCDA) presentation at the A.G.P. Healthcare Showcase?
